Follow The Filings

TRDA Entrada Therapeutics

Entrada Therapeutics earnings company data as of 4:00 PM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS -0.99 — —
Rev $5.3M — —

Insider trades

Open-market buys and sales by TRDA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TRDA insider trades
  • $1.6M bought by 2 insiders
  • $13.8M sold by 4 insiders outside a trading plan
  • $1.3M sold by 3 insiders under 10b5-1 plans
  1. Mpm Bioventures 2018, L.P. 10% owner, +2 joint filers
    Sale
    $1.9M 259,837 shares at $7.33 6.3% of stake
    Traded Sep 4–9 Filed Sep 9
  2. Mpm Bioventures 2018, L.P. 10% owner, +2 joint filers
    Sale
    $617K 86,482 shares at $7.14 2% of stake
    Traded Sep 1–3 Filed Sep 3
  3. Mpm Bioventures 2018, L.P. 10% owner, +2 joint filers
    Sale
    $616K 86,914 shares at $7.08 2% of stake
    Traded Aug 27–31 Filed Aug 31
  4. MPM BioVentures 2014, L.P. 10% owner, +9 joint filers
    Sale
    $462K 62,714 shares at $7.36 1.4% of stake
    Traded Aug 24–26 Filed Aug 26
  5. Kush Parmar Director
    Sale
    $1.1M 155,255 shares at $6.95 5.5% of stake
    Traded Aug 6–10 Filed Aug 10
  6. 5AM Ventures V, L.P. 10% owner, +5 joint filers
    Sale
    $432K 62,811 shares at $6.88 2.2% of stake
    Traded Aug 6–7 Filed Aug 10
  7. Kush Parmar Director
    Sale
    $807K 116,474 shares at $6.93 3.9% of stake
    Traded Jul 30–31 Filed Aug 3
  8. Bernhardt G Zeiher Director
    Buy
    $29K 5,000 shares at $5.86 New stake
    Traded May 20 Filed May 21
  9. Natarajan Sethuraman President, Research & Develop.
    Planned sale
    $399K 25,907 shares at $15.39 11% of stake
    Traded May 4 Filed May 4
  10. Nathan J Dowden COO
    Planned sale
    $230K 15,000 shares at $15.33 7% of stake
    Traded May 4 Filed May 4

Also filed in the last 12 months, not counted as buying or selling: 12 share withholdings for taxes, 4 stock grants, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
SCHEDULE 13D/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02,5.07,9.01
8-K 7.01,9.01
8-K 2.02,7.01,9.01
10-Q
DEFA14A
DEF 14A
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf